Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719282 | 0.85 | KMT2A (0.54) | KMT2AMAPK14NPC1RAB9AKCNK3 | |
| SCHEMBL13596551 | 0.82 | KCNQ3 (0.46) | KMT2ANPC1RAB9AHDAC1 | |
| SCHEMBL13969806 | 0.79 | TP53 (0.45) | KMT2ANPC1RAB9A | |
| SCHEMBL14345216 | 0.77 | ABL1 (0.43) | KMT2AMAPK14NPC1RAB9AHPGD | |
| SCHEMBL13907634 | 0.75 | RAB9A (0.54) | KMT2ANPC1RAB9AHPGD | |
| SCHEMBL10227043 | 0.73 | KMT2A (0.67) | KMT2AMAPK14NPC1RAB9AKCNK3 | |
| SCHEMBL13973650 | 0.73 | TSHR (0.36) | KMT2ANPC1RAB9A | |
| SCHEMBL10264645 | 0.71 | MAPK14 (0.42) | KMT2AMAPK14NPC1RAB9ALCK | |
| SCHEMBL10274170 | 0.70 | MAPK14 (0.46) | KMT2AMAPK14LCK | |
| SCHEMBL2718631 | 0.70 | KMT2A (0.63) | KMT2AMAPK14NPC1RAB9AKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20100144755-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100093765-A1 | NOVEL COMPOUNDS | CALLAHAN JAMES F | 2010-04-15 | — | — | US | disclosed |
| US-20100093766-A1 | NOVEL COMPOUNDS | CALLAHAN JAMES F | 2010-04-15 | — | — | US | disclosed |
| US-7674789-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090239846-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-09-24 | — | — | US | disclosed |
| US-20090156597-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090069318-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144755-A1 | Novel Compounds | MAPKAPK2, CDC42BPB, MAPK8 | KMT2A 2863/4885MAPK14 35/4885NPC1 2139/4885 |
| US-20100093766-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | KMT2A 2825/4885MAPK14 46/4885NPC1 1584/4885 |
| US-20090239846-A1 | Novel Compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | KMT2A 2825/4885MAPK14 46/4885NPC1 1584/4885 |
| US-20100093765-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | KMT2A 2825/4885MAPK14 46/4885NPC1 1584/4885 |
| US-20090156597-A1 | Novel Compounds | MAPKAPK2, MAPK8, MAPKAPK3 | KMT2A 2325/4885MAPK14 43/4885NPC1 1885/4885 |
| US-20090069318-A1 | Novel Compounds | MAPKAPK2, MAPK8, MAPKAPK3 | KMT2A 2325/4885MAPK14 43/4885NPC1 1885/4885 |
| US-20090318424-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | KMT2A 2825/4885MAPK14 46/4885NPC1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.